| 查看: 1474 | 回复: 17 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
关于SCI杂志发表挂名
已经有32人回复
-
考研调剂：国家蛋白质科学中心（国家重点实验室）和安徽医科大学基础医学院联培
已经有4人回复
-
药物学论文润色/翻译怎么收费?
已经有117人回复
-
华南理工大学 基础医学学硕和临床医学学硕调剂
已经有11人回复
-
医药研发数据库资源
已经有4人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
求助中国药典1995年版、二部
已经有0人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
求助https://www.pnas.org/doi/10.1073/pnas.2535777123 全文
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
告别流水线爽文！108万字完结仙侠《女娲石之灵石奇缘（仙界篇）》值得细品
+1/9017
-
散金祈福
+5/1055
-
每年这时候我都再仔细读一遍《范进中举》
+1/472
-
华西生物制药研究院招聘科研助理
+2/398
-
基金申请小调查！预祝申请必定中中中！！祈福！！！
+5/230
-
诚征另一半
+1/168
-
上海交通大学张航课题组招聘博士后（电化学储能）
+1/89
-
Polymers 期刊特刊 组稿
+1/75
-
焦虑
+1/64
-
哈尔滨工业大学（校本部）电子与信息工程学院2027级博士招生
+1/63
-
上海交通大学张航课题组招聘博士后（电化学能量存储与转换）
+1/43
-
瑞典-博后-固态电池-粘结剂-锂离子电池方向
+1/35
-
瑞典-博后-固态电池-粘结剂-锂离子电池方向
+1/33
-
南京理工大学优青团队催化化学方向招收推免研究生
+1/22
-
流放岭南浮肿了求救
+1/18
-
上海交通大学化学化工学院倪伟焱课题组招收2027年申请考核制博士生（电催化+高分子）
+1/12
-
北理工集成电路杰青团队 | 诚招科助理
+1/7
-
2027环境工程博士申请
+1/7
-
祈祷老公中国基
+1/4
-
出全新蔡司 Plan?APOCHROMAT 20×/0.8 平场复消色差物镜
+1/2
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
10楼2015-09-01 08:19:15
11楼2015-09-14 11:50:36
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
本帖内容被屏蔽 |
14楼2015-09-17 14:21:15
简单回复
dmbb2楼
2015-08-31 14:57
回复
飞飞-笑笑(金币+1): 谢谢参与
2015-08-31 15:06
回复
飞飞-笑笑(金币+1): 谢谢参与
我是谁博文4楼
2015-08-31 15:15
回复
飞飞-笑笑(金币+1): 谢谢参与
2015-08-31 15:27
回复
飞飞-笑笑(金币+1): 谢谢参与
一米阳光YM6楼
2015-08-31 15:45
回复
飞飞-笑笑(金币+1): 谢谢参与
hr.wu8楼
2015-08-31 16:34
回复
fishyr12楼
2015-09-17 14:10
回复
liubopeng13楼
2015-09-17 14:11
回复
10
小白112615楼
2015-09-17 17:07
回复
1808466628316楼
2015-09-17 17:22
回复
xdon041717楼
2015-09-17 22:30
回复
William.Chen18楼
2015-09-17 23:25
回复
